{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:03:16Z","timestamp":1792598596578,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.endien.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T11:51:04Z","timestamp":1654861864000},"page":"354-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes"],"prefix":"10.1016","volume":"69","author":[{"given":"Fatma Nur","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asena","family":"G\u00f6k\u00e7ay Canpolat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"G\u00fcll\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.endien.2022.05.006_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00592-017-1066-y","article-title":"Errors in insulin treatment management and risk of lipohypertrophy","volume":"55","author":"Pozzuoli","year":"2018","journal-title":"Acta Diabetol"},{"key":"10.1016\/j.endien.2022.05.006_bib0125","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13300-016-0161-3","article-title":"Frequency of lipohypertrophy and associated risk factors in young patients with type 1 diabetes: a cross-sectional study","volume":"7","author":"Al Hayek","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.endien.2022.05.006_bib0130","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1007\/s13300-020-00876-0","article-title":"Insulin-induced skin lipohypertrophy in type 2 diabetes: a multicenter regional survey in Southern Italy","volume":"11","author":"Gentile","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.endien.2022.05.006_bib0135","first-page":"42","article-title":"Factors hindering correct identification of unapparent lipohypertrophy","volume":"3","author":"Gentile","year":"2016","journal-title":"J Diabetes Metab Disord Contr"},{"key":"10.1016\/j.endien.2022.05.006_bib0140","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.mayocp.2016.06.011","article-title":"Worldwide injection technique questionnaire study: population parameters and injection practices","volume":"91","author":"Frid","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.endien.2022.05.006_bib0145","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s40064-016-1978-y","article-title":"A suitable palpation technique allows to identify skin lipohypertrophic lesions in insulin-treated people with diabetes","volume":"5","author":"Gentile","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.endien.2022.05.006_bib0150","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/dme.13764","article-title":"Ultrasound detection of insulin-induced lipohypertrophy in Type 1 and Type 2 diabetes","volume":"35","author":"Kapeluto","year":"2018","journal-title":"Diabetic Med"},{"key":"10.1016\/j.endien.2022.05.006_bib0155","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.diabres.2006.12.023","article-title":"Incidence of lipohypertrophy in diabetic patients and a study of influencing factors","volume":"77","author":"Vardar","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.endien.2022.05.006_bib0160","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.diabet.2013.05.006","article-title":"Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes","volume":"39","author":"Blanco","year":"2013","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.endien.2022.05.006_bib0165","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.dsx.2018.11.042","article-title":"Why are so huge differences reported in the occurrence rate of skin lipohypertrophy? Does it depend on method defects or on lack of interest?","volume":"13","author":"Gentile","year":"2019","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.endien.2022.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1007\/s13300-018-0472-7","article-title":"A systematic review of ultrasound-detected lipohypertrophy in insulin-exposed people with diabetes","volume":"9","author":"Abu Ghazaleh","year":"2018","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.endien.2022.05.006_bib0175","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.diabet.2016.04.010","article-title":"Skin and subcutaneous tissue thickness at insulin injection sites in Chinese diabetes patients: clinical implications","volume":"42","author":"Wang","year":"2016","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.endien.2022.05.006_bib0180","first-page":"104","article-title":"Ultrasonographic aspect of subcutaneous tissue dystrophies as a result of insulin injections","volume":"12","author":"Perciun","year":"2010","journal-title":"Med Ultrasonogr"},{"key":"10.1016\/j.endien.2022.05.006_bib0185","article-title":"Subclinical lipohypertrophy \u2013 easily ignored complications of insulin therapy","author":"Luo","year":"2020","journal-title":"J Diabetes Compl"},{"key":"10.1016\/j.endien.2022.05.006_bib0190","series-title":"17th European Congress of Endocrinology","article-title":"Insulin-induced lipohypertrophy diagnostics in diabetic patients: subcutaneous fat ultrasonography","author":"Natalya Volkova","year":"2017"},{"key":"10.1016\/j.endien.2022.05.006_bib0195","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s40618-017-0675-1","article-title":"Ultrasound characterization of insulin induced lipohypertrophy in type 1 diabetes mellitus","volume":"40","author":"Bertuzzi","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.endien.2022.05.006_bib0200","doi-asserted-by":"crossref","first-page":"107806","DOI":"10.1016\/j.jdiacomp.2020.107806","article-title":"Subclinical lipohypertrophy \u2013 easily ignored complications of insulin therapy","volume":"35","author":"Luo","year":"2021","journal-title":"J Diabetes Compl"},{"key":"10.1016\/j.endien.2022.05.006_bib0205","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0192623317696283","article-title":"Chronic toxicology studies of basal insulin peglispro in rats and dogs: a novel, PEGylated insulin lispro analog with a prolonged duration of action","volume":"45","author":"Byrd","year":"2017","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.endien.2022.05.006_bib0210","doi-asserted-by":"crossref","first-page":"638","DOI":"10.3389\/fendo.2018.00638","article-title":"Insulin-related lipohypertrophy: lipogenic action or tissue trauma?","volume":"9","author":"Barola","year":"2018","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.endien.2022.05.006_bib0215","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1055\/s-2001-18991","article-title":"Insulin antibodies are associated with lipoatrophy but also with lipohypertrophy in children and adolescents with type 1 diabetes","volume":"109","author":"Raile","year":"2001","journal-title":"Exp Clin Endocrinol"},{"key":"10.1016\/j.endien.2022.05.006_bib0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/dia.2016.0334","article-title":"Lipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact","volume":"19","author":"Ji","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.endien.2022.05.006_bib0225","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/01.ATV.20.3.830","article-title":"LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the strong heart study","volume":"20","author":"Howard","year":"2000","journal-title":"Arterioscl Thromb Vasc Biol"},{"key":"10.1016\/j.endien.2022.05.006_bib0230","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"}],"container-title":["Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018022000968?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2530018022000968?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:16:02Z","timestamp":1762866962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2530018022000968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S2530018022000968"],"URL":"https:\/\/doi.org\/10.1016\/j.endien.2022.05.006","relation":{},"ISSN":["2530-0180"],"issn-type":[{"value":"2530-0180","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determination of insulin-related lipohypertrophy frequency and risk factors in patients with diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrinolog\u00eda, Diabetes y Nutrici\u00f3n (English ed.)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.endien.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 SEEN and SED. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}